Your Article Summary
See Latest ArticlesPrognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
Endocrine-Related Cancer, 06/05/09
Durante C et al. - In a study to evaluate the long-term outcome and prognostic factors for survival in pts with distant metastases from gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC), this study enables the stratification of metastatic GEP WDEC pts into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and to design and interpret clinical trials.
Methods- Long-term outcome and prognostic factors for survival were evaluated in 118 pts with distant metastases from GEP WDEC.
- Inclusion criteria included pathological review by a single pathologist according to WHO criteria, absence of previous therapy apart from surgery, complete morphological evaluation within 3 mos including somatostatin receptor scintigraphy, and follow-up at Gustave-Roussy Institute until death or study's end.
- Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models.
- Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan–Meier method.
- Survival for 5 yrs after diagnosis of metastatic disease was 54%.
- In multivariate analysis, age, number of liver metastases, tumor slope, and initial surgery were predictive of survival.
- 5-yr survival was 100%, 91%, 62%, and 9% when pts had 0, 1, 2, 3, or more poor prognostic features, respectively.
Related Articles
Neurofibroma adjacent to the thyroid gland and a thyroid papillary carcinoma in a patient with neurofibromatosis type 1: Report of a case
Surgery Today, 10/06/09
Relevance Score: 66%
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification
Histopathology, 11/11/09
Relevance Score: 65%
S100A8 and S100A9 Expression Is a Crucial Factor for Dedifferentiation in Thyroid Carcinoma
Anticancer Research, 11/11/09
Relevance Score: 65%
Continuous 5-fluorouracil infusion plus long acting Octreotide in advanced well differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network.
BMC Cancer, 11/09/09
Relevance Score: 65%
RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact
Journal of Clinical Endocrinology and Metabolism, 10/21/09
Relevance Score: 65%
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimotos thyroiditis
Histopathology, 12/04/09
Oncocytic versus mitochondrion-rich follicular thyroid tumours: should we make a difference
Histopathology, 12/04/09
Clinical inquiry: What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer?
The Journal of Family Practice, 12/03/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
Medical Oncology, 12/04/09
Clinicopathological characteristics of primary gastric T-cell lymphoma
Histopathology, 12/04/09
Today in Hepatobiliary/Pancreas...keeping you current
Receive free subspecialty "5-minute updates" via email
Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB
Journal of Cancer Research & Clinical Oncology, 12/04/09
Quantitative measurement of venous invasion of colorectal cancer with metachronous liver metastasis
Histopathology, 12/04/09
Histological type of Thorotrast-induced liver tumors associated with the translocation of deposited radionuclides
Cancer Science, 12/04/09